MDM2 and cancer: Among the target compounds, one spirooxindole-based hydroxamic acid 11b exhibited comparable inhibitory activities among MDM2 and HDAC, it also possessed good in vitro activity toward the tested three cancer cells, especially MCF-7, reaching the IC50 value of 1.37 ± 0.45 μM.